A prospective study of serum metabolites and risk of ischemic stroke.

Biomarkers / blood Brain Ischemia / blood Female Follow-Up Studies Genetic Association Studies Humans Incidence Male Metabolome Metabolomics Middle Aged Polymorphism, Single Nucleotide Prospective Studies Risk Factors Stroke / blood

Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
16 04 2019
Historique:
received: 20 10 2017
accepted: 19 12 2018
pubmed: 15 3 2019
medline: 8 1 2020
entrez: 15 3 2019
Statut: ppublish

Résumé

To identify promising blood-based biomarkers and novel etiologic pathways of disease risk, we applied an untargeted serum metabolomics profiling in a community-based prospective study of ischemic stroke (IS). In 3,904 men and women from the Atherosclerosis Risk In Communities study, Cox proportional hazard models were used to estimate the association of incident IS with the standardized level of 245 fasting serum metabolites individually, adjusting for age, sex, race, field center, batch, diabetes, hypertension, current smoking status, body mass index, and estimated glomerular filtration rate. Validation of results was carried out in an independent sample of 114 IS cases and 112 healthy controls. Serum levels of 2 long-chain dicarboxylic acids, tetradecanedioate and hexadecanedioate, were strongly correlated ( Two serum long-chain dicarboxylic acids, metabolic products of ω-oxidation of fatty acids, were associated with IS and CES independently of known risk factors. Pathways related to intracellular hexadecanedioate synthesis or those involved in its clearance from the circulation may mediate IS risk. These results highlight the potential of metabolomics to discover novel circulating biomarkers for stroke and to unravel novel pathways for IS and its subtypes.

Identifiants

DOI: 10.1212/WNL.0000000000007279 PMID: 30867269 PMC: PMC6550501
pubmed: 30867269
pii: WNL.0000000000007279
doi: 10.1212/WNL.0000000000007279
pmc: PMC6550501
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1890-e1898

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS087541
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG052409
Pays : United States

Informations de copyright

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

J Biol Chem. 1998 Feb 13;273(7):3937-42
pubmed: 9461579
J Clin Bioinforma. 2011 Mar 8;1:
pubmed: 21743835
PLoS One. 2015 Nov 06;10(11):e0142610
pubmed: 26544570
Stroke. 2013 Mar;44(3):870-947
pubmed: 23370205
Anal Chem. 2009 Aug 15;81(16):6656-67
pubmed: 19624122
Int J Cardiol. 2014 Dec 20;177(3):754-63
pubmed: 25465824
Eur J Vasc Endovasc Surg. 2016 Jul;52(1):5-10
pubmed: 27231199
FEBS J. 2011 Jan;278(2):182-94
pubmed: 21156023
J Med Chem. 1989 Sep;32(9):2072-84
pubmed: 2788743
Prostaglandins Other Lipid Mediat. 2016 Jan;122:45-53
pubmed: 26747234
PLoS One. 2017 Apr 12;12(4):e0175479
pubmed: 28403188
J Atheroscler Thromb. 2015;22(11):1148-57
pubmed: 25947240
Stat Med. 1997 Nov 30;16(22):2529-42
pubmed: 9403954
Am J Epidemiol. 1989 Apr;129(4):687-702
pubmed: 2646917
Stroke. 2011 May;42(5):1282-8
pubmed: 21474802
Neurochem Res. 1998 Feb;23(2):227-33
pubmed: 9475518
Stroke. 2016 Mar;47(3):895-900
pubmed: 26786114
Stroke. 1999 Apr;30(4):736-43
pubmed: 10187871
Nat Genet. 2014 Jun;46(6):543-550
pubmed: 24816252
Stroke. 2014 Nov;45(11):3219-25
pubmed: 25190443
Stroke. 1981 Mar-Apr;12(2 Pt 2 Suppl 1):I1-91
pubmed: 7222163
Circ Res. 2017 Feb 3;120(3):472-495
pubmed: 28154098
Hum Mol Genet. 2005 Oct 1;14(19):2829-37
pubmed: 16115816
Talanta. 2011 Apr 15;84(2):298-304
pubmed: 21376948
Clin Pharmacol Ther. 2016 Nov;100(5):524-536
pubmed: 27447836
Hypertension. 2015 Aug;66(2):422-9
pubmed: 26034203
Biochim Biophys Acta. 2015 Aug;1850(8):1555-65
pubmed: 25513966
Toxicol Pathol. 2009 Jun;37(4):521-35
pubmed: 19458390
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
Circ Res. 2017 Sep 29;121(8):970-980
pubmed: 28724745
Annu Rev Pharmacol Toxicol. 2005;45:413-38
pubmed: 15822183
Pharmacogenet Genomics. 2010 Mar;20(3):187-94
pubmed: 20130494
Nat Genet. 2018 Apr;50(4):524-537
pubmed: 29531354
Stroke. 2009 Nov;40(11):3646-78
pubmed: 19797189

Auteurs

Daokun Sun (D)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Steffen Tiedt (S)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Bing Yu (B)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Xueqiu Jian (X)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Rebecca F Gottesman (RF)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Thomas H Mosley (TH)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Eric Boerwinkle (E)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Martin Dichgans (M)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany.

Myriam Fornage (M)

From the Brown Foundation Institute of Molecular Medicine, McGovern Medical School (D.S., X.J., M.F.), and School of Public Health (B.Y., E.B., M.F.), The University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (S.T., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany; Johns Hopkins University School of Medicine (R.F.G.), Baltimore, MD; The University of Mississippi Medical Center (T.H.M.), Jackson; German Center for Neurodegenerative Diseases (DZNE, Munich) (M.D.); and Munich Cluster for Systems Neurology (SyNergy) (S.T., M.D.), Germany. Myriam.Fornage@uth.tmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › A prospective study of serum metabolites and...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Angiopathies intracrâniennes › Encéphalopathie ischémique › A prospective study of serum metabolites and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › A prospective study of serum metabolites and...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Études d'associations génétiques › A prospective study of serum metabolites and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A prospective study of serum metabolites and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › A prospective study of serum metabolites and...
questionsmedicales.fr › Métabolisme › Métabolome › A prospective study of serum metabolites and...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Métabolomique › A prospective study of serum metabolites and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › A prospective study of serum metabolites and...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › A prospective study of serum metabolites and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › A prospective study of serum metabolites and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › A prospective study of serum metabolites and...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Angiopathies intracrâniennes › Accident vasculaire cérébral › A prospective study of serum metabolites and...